[Carbogen therapy in high myopia in children].
Forty-eight patients, aged 7 to 15, with the diagnosis of high developed myopia complicated by chorioretinal peripheral dystrophy were investigated. A total of 1500 examinations were made. The patients were shared between the main and control groups. Sex, age and the clinical pattern were compatible. The main-group patients received the carbogene therapy and routine neurotrophic treatment, while the controls received only the latter. The treatment course lasted for as long as 10 days (10 inhalations). There were no any complications during and after the carbogene inhalations. The conclusion, based on the data obtained, can be that the carbogene inhalations, when added to the neurotrophic treatment scheme, enhance the therapy efficiency in case of high, complicated and developed myopia in children.
Sidorenko
E I
EI
Kenarskaia
E E
EE
D000293:Adolescent; D000367:Age Factors; D000596:Amino Acids / Q000627:therapeutic use; D002245:Carbon Dioxide / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002825:Chorioretinitis / Q000150:complications; D005260:Female; D006801:Humans; D008297:Male; D009216:Myopia / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D018696:Neuroprotective Agents / Q000627:therapeutic use; D010100:Oxygen / Q000008:administration & dosage / Q000627:therapeutic use*; D010431:Pentoxifylline / Q000627:therapeutic use; D012138:Respiratory Therapy; D012737:Sex Factors; D013654:Taurine / Q000627:therapeutic use; D013997:Time Factors; D014792:Visual Acuity; D014794:Visual Fields; D014803:Vitamin B Complex / Q000008:administration & dosage / Q000627:therapeutic use
D000596:Amino Acids; D018696:Neuroprotective Agents; D014803:Vitamin B Complex; D002245:Carbon Dioxide; D013654:Taurine; C006952:cerebrolysin; C011700:carbogen; D010100:Oxygen; D010431:Pentoxifylline